&p=W&b=5&g=0&id=p86431144783
Recent INAB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:00:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:07:54 PM
- IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 • GlobeNewswire Inc. • 06/13/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:53:31 PM
- IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 06/03/2024 10:05:00 AM
- IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 • GlobeNewswire Inc. • 05/24/2024 12:00:00 PM
- IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
- IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress • GlobeNewswire Inc. • 05/14/2024 02:00:00 PM
- IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:06:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:04:17 PM
- IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 05/09/2024 08:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/07/2024 08:05:48 PM
- IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma • GlobeNewswire Inc. • 04/30/2024 10:05:00 AM
- IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting • GlobeNewswire Inc. • 04/24/2024 12:00:00 PM
- IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/16/2024 08:05:00 PM
- IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 • GlobeNewswire Inc. • 04/09/2024 08:30:00 PM
- IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 03/14/2024 08:00:00 PM
- IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- IN8bio to Present at Upcoming Investor Conferences • Business Wire • 02/26/2024 01:00:00 PM
- IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology • GlobeNewswire Inc. • 02/14/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:54:21 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM